alm-488
Peptideexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Jun 30, 2020 (NCT04420689)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095488 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06662097 | Phase 2 | Oct 16, 2024 | Alume Biosciences, Inc. |
| NCT06227585 | Phase 2 | Nov 29, 2023 | Alume Biosciences, Inc., University of California, San Francisco |
| NCT05377554 | Phase 3 | Apr 29, 2022 | Alume Biosciences, Inc., Ergomed, University of California, San Diego |
| NCT04420689 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2020 | Alume Biosciences, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alume Biosciences, Inc. | For profit | 4 | 4 | 2 | 2020 |
| Ergomed | For profit | 1 | 0 | 1 | 2022 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1